EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Potential miR‐1246‐5p–H3K27ac–NOL12 Regulatory Axis and Its Putative Tumour‐Promoting Function in Hepatocellular Carcinoma

Li Xiao, Yu-Long Deng, Li-Na Liang, Jian-Di Li, Dong-Ming Li, Qi Li, Bin Li, Rong-Quan He, Da-Tong Zeng, Yi-Wu Dang, Gang Chen iD

IET Systems Biology · 2026-01 · 20 (1)

DOI: 10.1049/syb2.70071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IET Systems Biology, online erschienen am 21.07.2026. Verfasst von Li Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Liver Neoplasms, MicroRNAs, Carcinoma, Hepatocellular, Nuclear Proteins. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi, China, Innovation Project of Guangxi Graduate Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a major cause of cancer‐related death worldwide. Although the nucleolar protein NOL12 has been implicated in HCC progression, its comprehensive expression patterns, clinical significance and regulation—particularly the potential involvement of miR‐1246‐5p and H3K27ac—are not fully understood, warranting further investigation. To analyse the expression pattern and clinical significance of NOL12, we integrated bulk RNA sequencing (bulk RNA‐seq) data (4264 HCC cases vs. 3145 non‐HCC cases), single‐cell RNA sequencing (scRNA‐seq) data (12 HCC samples) and spatial transcriptomics (ST) data from public databases including GEO, TCGA and GTEx. This integration was combined with in‐house immunohistochemistry (IHC) data from 394 pairs of HCC tissues and adjacent non‐tumour tissues. CRISPR screening was used to assess the effect of NOL12 depletion on HCC cell proliferation. Seven immune infiltration analysis methods (including CIBERSORT) were applied to the TCGA‐GTEx dataset to explore the association between NOL12 and the tumour immune microenvironment (TME). Gene ontology (GO) enrichment, Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway and Gene Set Enrichment Analysis (GSEA) were performed based on NOL12‐associated genes involved in HCC initiation and progression. Additionally, chromatin immunoprecipitation sequencing (ChIP‐seq) data from Cistrome DB were used to predict and construct the miR‐1246‐5p–enhancer–NOL12 regulatory network. Potential high‐affinity drug molecules targeting NOL12 were screened via the Cancer Therapeutics Response Portal (CTRP) database and molecular docking. Multi‐dimensional analysis revealed significant upregulation of NOL12 in HCC (SMD = 0.64, 95% CI: 0.42–0.85; sROC AUC = 0.79). IHC validation confirmed higher NOL12 expression in HCC tissues ( p < 0.0001, ROC AUC = 0.665). CRISPR screening showed that NOL12 depletion inhibited HCC cell proliferation. Mechanistically, NOL12 was enriched in the spliceosome pathway. ChIP‐seq identified an H3K27ac‐modified enhancer in the NOL12 promoter overlapping with miR‐1246‐5p binding sites, and miR‐1246‐5p expression positively correlated with NOL12 ( r = 0.43, p = 0.018). Drug sensitivity prediction analysis showed that NOL12 protein exhibited significant sensitivity to BRD‐K71781559, MST‐312, IU1, BRD9876 and PRL‐3 inhibitor I, with favourable binding energies. NOL12 may be regulated by the putative miR‐1246‐5p/H3K27ac enhancer axis and promotes HCC progression through the spliceosome pathway, supporting its potential as a novel therapeutic target for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsMicroRNAsCarcinoma, HepatocellularNuclear ProteinsHistonesHumansGene Expression Regulation, NeoplasticCell Line, TumorCell Proliferation

Stichwörter der Autor:innen

data analysisdata mininggenomicslivertumours

Substanzen

MicroRNAsMIRN1246 microRNA, humanNuclear ProteinsHistones

Autor:innen und Institutionen

  • Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Pathology, Wuming Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Pathology, Yulin Red Cross Hospital, Yulin, China.

ORCID-Profile: Gang Chen

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangxi, China
  • Innovation Project of Guangxi Graduate Education
  • Guangxi Medical University 'Four New' Project
  • Guangxi Medical University Special Project on Educational and Teaching Reform for Clinical Disciplines
  • Future Academic Star of Guangxi Medical University
  • Advanced Innovation Teams and Xinghu Scholars Program of Guangxi Medical University

Zitieren

APA

Xiao, L., Deng, Y. L., Liang, L. N., Li, J. D., Li, D. M., Li, Q., Li, B., He, R. Q., Zeng, D. T., Dang, Y. W., & Chen, G. (2026). A Potential miR‐1246‐5p–H3K27ac–NOL12 Regulatory Axis and Its Putative Tumour‐Promoting Function in Hepatocellular Carcinoma. IET Systems Biology, 20(1). https://doi.org/10.1049/syb2.70071

Vancouver

Xiao L, Deng YL, Liang LN, Li JD, Li DM, Li Q, et al. A Potential miR‐1246‐5p–H3K27ac–NOL12 Regulatory Axis and Its Putative Tumour‐Promoting Function in Hepatocellular Carcinoma. IET Systems Biology. 2026;20(1). doi:10.1049/syb2.70071

BibTeX
@article{Xiao2026,
  author = {Xiao, Li and Deng, Yu-Long and Liang, Li-Na and Li, Jian-Di and Li, Dong-Ming and Li, Qi and Li, Bin and He, Rong-Quan and Zeng, Da-Tong and Dang, Yi-Wu and Chen, Gang},
  title = {A Potential miR‐1246‐5p–H3K27ac–NOL12 Regulatory Axis and Its Putative Tumour‐Promoting Function in Hepatocellular Carcinoma},
  journal = {IET Systems Biology},
  year = {2026},
  volume = {20},
  number = {1},
  doi = {10.1049/syb2.70071}
}
Kostenlos starten →